Disease Name: Alzheimer disease Disease Synonym: Alzheimer's disease Pathophysiology comments: Alzheimer's disease. Inhbition of C5aR, through oral administration of PMX205, in these models reduces Pathophysiology role: Alzheimer's disease anti-PD1 antibody treatment was used to induce immune checkpoint blockade. The biological Pathophysiology role: neurons and may be a potential therapeutic target for the treatment of Alzheimer's disease
Comments: compound is being repurposed since the p38alpha mechanism may modulate Alzheimer's specific inflammatory processes . Clinical use: Alzheimer's disease in June 2015. These trials, NCT02423200 and NCT02423122, have now been completed Immuno Ligand Comments: Alzheimer's disease, as predicted by preclinical assessment in a mouse model of the disease
Comment: cancer , and evidence that suggests that NLRP1 and NLRP3 inflammasomes are activated in Alzheimer's disease . Mutations/pathophysiology - disease: Alzheimer disease Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease
Consequences of altering gene expression: implicated in Alzheimer's disease and is elevated in the sporadic Alzheimer's disease brain. Consequences of altering gene expression: accumulation of the amyloid-beta peptide in vitro and in an Alzheimer's disease mouse model Mutations/pathophysiology - disease: Alzheimer disease Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease Mutations/pathophysiology - role: neurons and may be a potential therapeutic target for the treatment of Alzheimer's disease
Gene Expression and Pathophysiology: Upregulation in reactive astrocytes around amyloid plaques in mouse Alzheimer models Gene Expression and Pathophysiology: Alzheimer's disease
Comments: Alzheimer's disease. Compounds of different chemotypes are being explored as tools to further optimise Clinical use: compound to treat Alzheimer's disease has been assessed in a Phase 2a study (NCT01428453).